健康なボランティア(HVS)およびアトピー性皮膚炎(AD)の成人患者におけるBBT001の研究
HVSおよびAD患者におけるBBT001の安全性、忍容性、薬物動態、免疫原性、薬力学、臨床活性を評価するための、無作為化、盲検化、プラセボ対照、単一および複数回アッシング用量研究
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
調査の概要
詳細な説明
This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Lisa Li
- 電話番号:+1 617-848-6188
- メール:Lisa.Li@bambusatx.com
研究場所
-
-
California
-
Irvine、California、アメリカ、92614
- 募集
- First OC Dermatology
-
-
New York
-
New York、New York、アメリカ、10128
- 募集
- OptiSkin Medical
-
The Bronx、New York、アメリカ、10455
- 募集
- Equity Medical, LLC
-
-
-
-
Western Australia
-
Fremantle、Western Australia、オーストラリア、6160
- 募集
- Fremantle Dermatology
-
Perth、Western Australia、オーストラリア、6009
- 完了
- Linear Clinical Research
-
-
-
-
-
Christchurch、ニュージーランド
- 募集
- Optimal Clinical Trials Ltd - Christchurch
-
Upper Hutt、ニュージーランド、5018
- 募集
- Pacific Clinical Research Network (PCRN) Wellington
-
コンタクト:
- Tim Humphrey
-
-
Auckland
-
Grafton、Auckland、ニュージーランド、1010
- 募集
- Optimal Clinical Trials Central Auckland
-
コンタクト:
- Arna Letica
-
Otahuhu、Auckland、ニュージーランド、2025
- 引きこもった
- Aotearoa Clinical Trials
-
Takapuna、Auckland、ニュージーランド、0622
- 募集
- Pacific Clinical Research Network (PCRN) - Auckland
-
コンタクト:
- Paul Hamilton
-
-
-
-
-
Lodz、ポーランド、91-347
- 募集
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
-
Rzeszów、ポーランド、35-055
- 募集
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
-
Warsaw、ポーランド、02-507
- 募集
- Państwowy Instytut Medyczny MSWiA
-
Wroclaw、ポーランド、50-566
- 募集
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
1. History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
実験的:Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers. |
BBT001 will be administered |
|
実験的:Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
プラセボコンパレーター:Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers |
Placebo will be administered |
|
プラセボコンパレーター:Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers. |
Placebo will be administered |
|
プラセボコンパレーター:Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
アクティブコンパレータ:Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
プラセボコンパレーター:Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers |
Placebo will be administered |
|
アクティブコンパレータ:Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
プラセボコンパレーター:Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
アクティブコンパレータ:Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis |
BBT001 will be administered |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with adverse events following single and multiple administration of BBT001
時間枠:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in serum blood parameters
時間枠:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Laboratory assessments include hematology, blood chemistry and coagulation test |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in vital sign measurements following treatment administration.
時間枠:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Blood pressure and heart rate will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in physical examination following treatment administration.
時間枠:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Physical examination will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in 12-lead ECG readings
時間枠:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
12-lead ECG will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Maximum observed concentration of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum PK Tmax will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Area under the curve (AUC)
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Area under the curve of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Volume of distribution (Vz)
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Volume of distribution of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Total clearance (CL)
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Total clearance of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Elimination Half-life (t1/2).
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Elimination half-life of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
時間枠:At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum Anti-Drug Antibodies will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Lisa Li、Bambusa Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BBT001-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。